IL5 and asthma: In severe asthma, there are different biological therapies available, as detailed in Table 2, such as anti-immunoglobulin E (anti-IgE) therapy (omalizumab), anti-interleukin-5 (anti-IL-5) (mepolizumab, reslizumab), anti-alpha subunit-IL-5 receptor (benralizumab), an anti-alpha subunit of the IL-4 receptor/IL-13 receptor (dupilumab) or anti-thymic stromal lymphopoietin (TSLP) (tezepelumab).